Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Integrating electrospun aligned fiber scaffolds with bovine serum albumin-basic fibroblast growth factor nanoparticles to promote tendon regeneration.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, 2003-
    • Subject Terms:
      Fibroblast Growth Factor 2*/pharmacology ; Fibroblast Growth Factor 2*/chemistry ; Tissue Scaffolds*/chemistry ; Nanofibers*/chemistry ; Mesenchymal Stem Cells*/drug effects ; Mesenchymal Stem Cells*/cytology ; Nanoparticles*/chemistry ; Tissue Engineering*/methods ; Polyesters*/chemistry ; Serum Albumin, Bovine*/chemistry ; Regeneration*/drug effects ; Cell Differentiation*/drug effects ; Rats, Sprague-Dawley*; Animals ; Humans ; Rats ; Achilles Tendon/drug effects ; Tendons/drug effects ; Tendons/cytology ; Male ; Tendon Injuries/therapy ; Cattle
    • Abstract:
      Competing Interests: Declarations. Ethics approval and consent to participate: This project was under the approval of the institutional review board at the Ethics Committee of the First Affiliated Hospital of Zunyi Medical University. Consent for publication: All participating patients signed the informed consents before enrolled in the trial. Competing interests: The authors declare no competing interests.
      Background: Electrospun nanofiber scaffolds have been widely used in tissue engineering because they can mimic extracellular matrix-like structures and offer advantages including high porosity, large specific surface area, and customizable structure. In this study, we prepared scaffolds composed of aligned and random electrospun polycaprolactone (PCL) nanofibers capable of delivering basic fibroblast growth factor (bFGF) in a sustained manner for repairing damaged tendons.
      Results: Aligned and random PCL fiber scaffolds containing bFGF-loaded bovine serum albumin (BSA) nanoparticles (BSA-bFGF NPs, diameter 146 ± 32 nm) were fabricated, respectively. To validate the viability of bFGF-loaded aligned PCL nanofiber scaffold (aPCL + bFGF group) in tendon tissue engineering, we assessed the in vitro differentiation of human amniotic mesenchymal stem cells (hAMSCs) towards a tenogenic lineage and the in vivo regeneration of tendons using a rat Achilles tendon defect model. The encapsulated bFGF could be delivered in a sustained manner in vitro. The aPCL + bFGF scaffold promoted the in vitro differentiation of human amniotic mesenchymal stem cells (hAMSCs) towards a tenogenic lineage. In the repair of a rat Achilles tendon defect model, the aPCL + bFGF group showed a better repair effect. The scaffold offers a promising substrate for the regeneration of tendon tissue.
      Conclusions: The aligned and random PCL fiber scaffolds containing bFGF nanoparticles were successfully prepared, and their physical and chemical properties were characterized. The aPCL + bFGF scaffold could promote the expression of the related genes and proteins of tendon-forming, facilitating tendon differentiation. In the rat Achilles tendon defect experiments, the aPCL + bFGF exhibited excellent tendon regeneration effects.
      (© 2024. The Author(s).)
    • References:
      Mater Sci Eng C Mater Biol Appl. 2021 Jul;126:112181. (PMID: 34082981)
      Boll Soc Ital Biol Sper. 1982 Nov 30;58(22):1478-84. (PMID: 7165757)
      Biomaterials. 2021 Dec;279:121242. (PMID: 34768151)
      Int J Mol Sci. 2021 Oct 18;22(20):. (PMID: 34681872)
      Adv Drug Deliv Rev. 2019 Jun;146:209-239. (PMID: 30605737)
      Biomaterials. 2021 Oct;277:121083. (PMID: 34488121)
      Adv Healthc Mater. 2016 Jan 21;5(2):213-22. (PMID: 26606262)
      Int J Mol Sci. 2021 Jan 19;22(2):. (PMID: 33478081)
      Acta Biomater. 2015 Oct;25:240-52. (PMID: 26188325)
      ACS Biomater Sci Eng. 2020 Aug 10;6(8):4356-4376. (PMID: 33455173)
      Am J Sports Med. 2016 Aug;44(8):1998-2004. (PMID: 27159286)
      Int J Biol Macromol. 2021 Dec 15;193(Pt A):276-286. (PMID: 34687764)
      Bone. 2021 Dec;153:116172. (PMID: 34506992)
      Curr Eye Res. 1988 Jan;7(1):61-7. (PMID: 3359806)
      Acta Biomater. 2013 Dec;9(12):9442-50. (PMID: 23933048)
      Biomaterials. 2019 Dec;224:119488. (PMID: 31562997)
      Clin Sports Med. 2020 Apr;39(2):259-277. (PMID: 32115084)
      Tissue Eng Part A. 2021 Oct;27(19-20):1343-1354. (PMID: 33573468)
      Cell Death Dis. 2021 Nov 5;12(11):1049. (PMID: 34741033)
      Small. 2022 May;18(21):e2107714. (PMID: 35487761)
      Biomacromolecules. 2012 Nov 12;13(11):3650-60. (PMID: 23039047)
      Stem Cell Res Ther. 2021 Feb 12;12(1):126. (PMID: 33579346)
      Polymers (Basel). 2021 Aug 09;13(16):. (PMID: 34451183)
      J Control Release. 2021 May 10;333:448-486. (PMID: 33811983)
      Biofactors. 2021 Sep;47(5):768-777. (PMID: 34058037)
      Adv Exp Med Biol. 2014;802:31-47. (PMID: 24443019)
      JCI Insight. 2020 Jul 9;5(13):. (PMID: 32463804)
      Arthroscopy. 2021 Feb;37(2):435-437. (PMID: 33546782)
      Acta Biomater. 2020 Apr 1;106:328-341. (PMID: 32027991)
      Mater Sci Eng C Mater Biol Appl. 2021 Feb;119:111590. (PMID: 33321635)
      Nat Rev Rheumatol. 2010 May;6(5):262-8. (PMID: 20308995)
      Bioact Mater. 2022 Apr 01;19:24-37. (PMID: 35415312)
      Biomaterials. 2015 Jan;37:218-29. (PMID: 25453952)
      ACS Biomater Sci Eng. 2021 Feb 8;7(2):383-399. (PMID: 33492125)
      Stem Cell Res Ther. 2021 Apr 29;12(1):255. (PMID: 33926555)
      Acta Biomater. 2021 Oct 1;133:280-296. (PMID: 33894349)
      Acta Biomater. 2022 Jun;145:25-42. (PMID: 35470075)
      Cell Rep. 2022 Nov 22;41(8):111706. (PMID: 36417854)
      Am Fam Physician. 2019 Aug 1;100(3):147-157. (PMID: 31361101)
      Praxis (Bern 1994). 1998 Oct 28;87(44):1475-7. (PMID: 9847688)
      EBioMedicine. 2017 Jun;20:240-254. (PMID: 28566251)
      Biofabrication. 2019 Mar 04;11(2):025010. (PMID: 30829217)
      J Mater Sci Mater Med. 2010 Nov;21(11):2999-3008. (PMID: 20740306)
      Pharmaceutics. 2022 Jan 25;14(2):. (PMID: 35214010)
      Expert Opin Biol Ther. 2020 Nov;20(11):1373-1379. (PMID: 32574078)
      Biofabrication. 2017 Mar 08;9(1):015025. (PMID: 28224971)
      Biomaterials. 2011 Jul;32(21):4806-15. (PMID: 21474176)
      Pediatrics. 2021 Jun;147(6):. (PMID: 33990459)
      Biomaterials. 2019 Jun;205:81-93. (PMID: 30909111)
      Biofabrication. 2017 Nov 14;9(4):044106. (PMID: 29134948)
      Biotechnol Prog. 2008 Jul-Aug;24(4):945-56. (PMID: 19194903)
      Sci Rep. 2018 Nov 21;8(1):17167. (PMID: 30464300)
      Biomed Res Int. 2017;2017:7360354. (PMID: 29085840)
      Adv Healthc Mater. 2021 May;10(9):e2002269. (PMID: 33694312)
    • Grant Information:
      BMU2022PY007 Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation; 52073014 National Natural Science Foundation of China; buctrc202020 Fundamental Research Funds for the Central Universities; 2022YFC2408200 National Key R&D Program of China
    • Contributed Indexing:
      Keywords: Drug release; Electrospun nanofiber; Fiber orientation; Tendon repair; Tissue engineering
    • Accession Number:
      103107-01-3 (Fibroblast Growth Factor 2)
      0 (Polyesters)
      24980-41-4 (polycaprolactone)
      27432CM55Q (Serum Albumin, Bovine)
    • Publication Date:
      Date Created: 20241228 Date Completed: 20241228 Latest Revision: 20250104
    • Publication Date:
      20250114
    • Accession Number:
      PMC11673375
    • Accession Number:
      10.1186/s12951-024-03022-1
    • Accession Number:
      39731092